

1 We Claim:

2
3 1. A sustained release dosage form comprising oxybutynin for use
4 in managing the plasma concentration of oxybutynin and dry mouth
5 associated with the use of oxybutynin, wherein the sustained dosage form
6 upon once daily administration is characterized by the sustained release of a
7 therapeutically effective dose of oxybutynin to a patient responsive to
8 oxybutynin for managing the plasma concentration and dry mouth associated
9 therewith.

10
11 2. The sustained release dosage form according to claim 1,
12 wherein the plasma concentration is proportional to the sustained release
13 dose.

14
15 3. The sustained release dosage form according to claim 1,
16 wherein the sustained release dosage form releases up to 25 mg per hour of
17 oxybutynin, or oxybutynin therapeutically acceptable salt.

18
19 4. The sustained release dosage form according to claim 1,
20 wherein the sustained release dosage form comprises up to 650 mg of
21 oxybutynin, or oxybutynin therapeutically acceptable salt.

22
23 5. A sustained release dosage form comprising oxybutynin an
24 pharmaceutically acceptable carrier for managing dry mouth associated with
25 oxybutynin, wherein the sustained release dosage form upon once daily use
26 is characterized by a sustained release therapeutically effective dose up to 25
27 mg per hour to a patient responsive to oxybutynin therapy to provide a
28 plasma concentration proportional to the sustained release dose for
29 managing dry mouth.

SUB
21
FILED 2020

26B
a1

1 6. Oxybutynin for use in providing a sustained release dosage
2 form comprising oxybutynin and a pharmaceutically acceptable carrier,
3 wherein the sustained release dosage form is characterized by comprising up
4 to 650 mg of oxybutynin and up to 450 mg of a pharmaceutically acceptable
5 carrier for releasing up to 25 mg per hour of oxybutynin to an oxybutynin
6 receptive environment.

7
8 7. A method for managing dry-mouth in a patient administered
9 oxybutynin, wherein the method comprises orally administering to the patient
10 a sustained release dosage form comprising an oxybutynin selected from the
11 group consisting of oxybutynin and its pharmaceutically acceptable salt, that
12 administers the oxybutynin in a controlled rate over twenty-four hours for
13 managing dry mouth in a patient.

14
15 8. A method for managing dry mouth in a patient administered
16 oxybutynin for the management of incontinence, wherein the method
17 comprises administering a sustained-release dose of 5 mg to 30 mg of a
18 member selected from the group consisting of oxybutynin and its
19 pharmaceutically acceptable salt up to twenty-four hours for managing dry
20 mouth in the patient.

21
22 9. A method for relaxing bladder muscles and for managing
23 concomitantly dry mouth in a patient administered oxybutynin hydrochloride,
24 wherein the method comprises administering 5 mg to 30 mg of oxybutynin
25 hydrochloride in a sustained rate up to twenty-four hours for producing the
26 intended effect.

27
28 10. A method for decreasing the incidence of dry-mouth in a patient
29 administered oxybutynin, wherein the method comprises orally administering

1 to the patient a sustained-release dosage form comprising an oxybutynin
2 selected from the group consisting of oxybutynin and its pharmaceutically
3 acceptable salt, that administers the oxybutynin in a controlled rate over
4 twenty-four hours for decreasing the incidence of dry-mouth in the patient.

5
6 11. A method for decreasing dry-mouth in a patient administered
7 oxybutynin for the management of incontinence, wherein the method
8 comprises administering a sustained-release dose of 5 mg to 30 mg of a
9 member selected from the group consisting of oxybutynin and its
10 pharmaceutically acceptable salt up to twenty-four hours for decreasing dry-
11 mouth in the patient.

12
13 12. A method for relaxing bladder muscles and for decreasing
14 concomitantly dry-mouth in a patient administered oxybutynin hydrochloride,
15 wherein the method comprises administering 5 mg to 30 mg of oxybutynin
16 hydrochloride in a sustained-rate up to twenty-four hours for producing the
17 intended effects.

18
19 13. The use of a sustained release dosage form in the manufacture
20 of once daily oxybutynin therapy and the management of dry mouth
21 associated therewith, which manufacture comprises the incorporation into a
22 sustained release dosage form adapted for once daily admittance into an
23 environment of use for oxybutynin therapy and concomitantly dry mouth
24 associated therewith.

25
26 14. The use of oxybutynin in the manufacture of a sustained release
27 dosage form indicated for oxybutynin therapy and for the management of dry
28 mouth associated therewith, the manufacture comprising the step of
29 incorporating oxybutynin into a sustained release dosage form, which when

SUB
A1

RECEIVED - 11/11/00

SUB
A2

Sub
A2

1 admitted daily into an environment of use release oxybutynin and provides
2 management of dry mouth associated therewith.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

RECEIVED - 11/11/11